CoChat
Sign Up
Cited by 2Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major DepressionCardiac Health and Mental Health

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Psychopharmacology for Social Anxiety Disorder

Blanco, Carlos, Bragdon, Laura, Schneier, Franklin R., Liebowitz, Michael R.·2014·Social Anxiety
DOI 10.1016/b978-0-12-394427-6.00022-4
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/b978-0-12-394427-6.00022-4

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 17 references

Research works printed but not linked: 98

  1. Allgulander, 1999, Paroxetine in social anxiety disorder: a randomized placebo-controlled study, Acta Psychiatrica Scandinavica, 100, 193, 10.1111/j.1600-0447.1999.tb10845.x · DOI
  2. Allgulander, 2004, Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine, Human Psychopharmacology: Clinical and Experimental, 19, 387, 10.1002/hup.602 · DOI
  3. Atmaca, 2003, An open clinical trial of reboxetine in the treatment of social phobia, Journal of Clinical Psychopharmacology, 23, 417, 10.1097/01.jcp.0000085419.74359.a4 · DOI
  4. Baldwin, 1999, Paroxetine in social phobia/social anxiety disorder. Randomized double-blind, placebo-controlled study. Paroxetine Study Group, British Journal of Psychiatry, 175, 120, 10.1192/bjp.175.2.120 · DOI
  5. Barnett, 2002, Efficacy of olanzapine in social anxiety disorder: a pilot study, Journal of Psychopharmacology, 16, 365, 10.1177/026988110201600412 · DOI
  6. Black, 1992, Fluoxetine for the treatment of social phobia, Journal of Clinical Psychopharmacology, 12, 293, 10.1097/00004714-199208000-00022 · DOI
  7. Blanco, 2003, The evidence-based pharmacological treatment of social anxiety disorder, International Journal of Neuropsychopharmacology, 6, 427, 10.1017/S1461145703003791 · DOI
  8. Blanco, 2003, Pharmacological treatment of social anxiety disorder: a meta- analysis, Depression & Anxiety, 18, 29, 10.1002/da.10096 · DOI
  9. Blomhoff, 2001, Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia, British Journal of Psychiatry, 179, 23, 10.1192/bjp.179.1.23 · DOI
  10. Birmaher, 2003, Fluoxetine for the treatment of childhood anxiety disorders, Journal of The American Academy of Child and Adolescent Psychiatry, 42, 415, 10.1097/01.CHI.0000037049.04952.9F · DOI
  11. Canton, 2012, Optimal treatment of social phobia: systematic review and meta-analysis, Neuropsychiatric Disease and Treatment, 8, 203
  12. Clark, 1991, The assessment and treatment of performance anxiety in musicians, American Journal of Psychiatry, 148, 598, 10.1176/ajp.148.5.598 · DOI
  13. Compton, 2001, Sertraline in children with social anxiety disorder: an open trial, Journal of The American Academy of Adolescent Psychiatry, 409, 564, 10.1097/00004583-200105000-00016 · DOI
  14. Davidson, 2004, Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder, Journal of Clinical Psychopharmacology, 24, 118, 10.1097/01.jcp.0000106222.36344.96 · DOI
  15. Davidson, 1993, Treatment of social phobia with clonazepam and placebo, Journal of Clinical Psychopharmacology, 13, 423, 10.1097/00004714-199312000-00008 · DOI
  16. Dunlop, 2007, Tiagabine for social anxiety disorder, Human Psychopharmacology: Clinical and Experimental, 22, 241, 10.1002/hup.846 · DOI
  17. Dursun, 2001, Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action?, Canadian Journal of Psychiatry, 46, 287, 10.1177/070674370104600316 · DOI
  18. Emmanuel, 2000, Bupropion-SR in treatment of social phobia, Depression and Anxiety, 12, 111, 10.1002/1520-6394(2000)12:2<111::AID-DA9>3.0.CO;2-3 · DOI
  19. Fahlen, 1995, Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake reuptake inhibitor brofaromine: a double-blind placebo-controlled study, Acta Psychiatrica Scandinavica, 92, 351, 10.1111/j.1600-0447.1995.tb09596.x · DOI
  20. Fairbanks, 1997, Open fluoxetine treatment of mixed anxiety disorders in children and adolescents, Journal of Child and Adolescent Psychopharmacology, 7, 17, 10.1089/cap.1997.7.17 · DOI
  21. Furmark, 2005, Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo, Biological Psychiatry, 58, 132, 10.1016/j.biopsych.2005.03.029 · DOI
  22. Gelernter, 1991, Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study, Archives of General Psychiatry, 48, 938, 10.1001/archpsyc.1991.01810340070009 · DOI · Paper page
  23. Gorman, 1985, Treatment of social phobia with atenolol, Journal of Clinical Psychopharmacology, 5, 298, 10.1097/00004714-198510000-00009 · DOI
  24. Gould, 1997, Cognitive-behavioral and pharmacological treatment for social phobia: A meta-analysis, Clinical Psychology: Science and Practice, 4, 291
  25. Greist, 2011, Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study, International Clinical Psychopharmacology, 26, 243, 10.1097/YIC.0b013e3283491fd5 · DOI
  26. Hedges, 2007, The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials, J Psychopharmacol, 21, 102, 10.1177/0269881106065102 · DOI
  27. Isolan, 2007, An open-label trial of escitalopram in children and adolescents with social anxiety disorder, Journal of Child and Adolescent Psychopharmacology, 17, 751, 10.1089/cap.2007.0007 · DOI
  28. Johnson, 2005, Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function, CNS Drugs, 19, 873, 10.2165/00023210-200519100-00005 · DOI
  29. Kasper, 2005, Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study, British Journal of Psychiatry, 186, 222, 10.1192/bjp.186.3.222 · DOI
  30. Katschnig, 1997, On behalf of the International Multicenter Clinical Trial Group on Moclobemide in Social Phobia: Moclobemide in social phobia: A double-blind, placebo-controlled clinical study, European Archives of Psychiatry and Clinical Neuroscience, 247, 71
  31. Katzelnick, 1995, Sertraline for social phobia: a double-blind, placebo-controlled crossover study, American Journal of Psychiatry, 152, 1368, 10.1176/ajp.152.9.1368 · DOI
  32. Kinrys, 2003, Valproic acid for the treatment of social anxiety disorder, International Clinical Psychopharmacology, 18, 169
  33. Lepola, 2004, Controlled-release paroxetine in the treatment of patients with social anxiety disorder, Journal of Clinical Psychiatry, 65, 222, 10.4088/JCP.v65n0213 · DOI
  34. Liebowitz, 2002, A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder, Journal of Clinical Psychiatry, 63, 66, 10.4088/JCP.v63n0113 · DOI
  35. Liebowitz, 2005, A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder, Journal of Clinical Psychiatry, 66, 238, 10.4088/JCP.v66n0213 · DOI
  36. Liebowitz, 2005, Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder, Archives of General Psychiatry, 62, 190, 10.1001/archpsyc.62.2.190 · DOI
  37. Liebowitz, 2003, Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study, Journal of Clinical Psychiatry, 64, 785, 10.4088/JCP.v64n0708 · DOI
  38. Lott, 1997, Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study, Journal of Clinical Psychopharmacology, 17, 255, 10.1097/00004714-199708000-00003 · DOI
  39. Lydiard, 1988, Alprazolam in the treatment of social phobia, Journal of Clinical Psychiatry, 49, 17
  40. Marks, 1979, Brief standard self-rating for phobic patients, Behavior Research and Therapy, 17, 263, 10.1016/0005-7967(79)90041-X · DOI · Paper page
  41. Mrakotsky, 2008, Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia, Journal of Anxiety Disorders, 22, 88, 10.1016/j.janxdis.2007.01.005 · DOI
  42. Muehlbacher, 2005, Mirtazapine treatment of social phobia in women: A randomized, double-blind, placebo- controlled study, Journal of Clinical Psychopharmacology, 25, 580, 10.1097/01.jcp.0000186871.04984.8d · DOI
  43. Munjack, 1990, Clonazepam in the treatment of social phobia: a pilot study, Journal of Clinical Psychiatry, 51, 35
  44. Munjack, 1991, A pilot study of buspirone in the treatment of social phobia, Journal of Anxiety Disorders, 5, 87, 10.1016/0887-6185(91)90019-P · DOI
  45. Noyes, 1997, Moclobemide in social phobia: a controlled dose-response trial, Journal of Clinical Psychopharmacology, 17, 247, 10.1097/00004714-199708000-00002 · DOI
  46. Ontiveros, 2008, Double–blind controlled study with clonazapam and placebo in social anxiety disorder, Salud Mental, 31, 299
  47. Pallanti, 2006, Resistant social anxiety disorder response to escitalopram, Clinical Practice and Epidemology in Mental Health, 13, 35, 10.1186/1745-0179-2-35 · DOI
  48. Pande, 1999, Treatment of social phobia with gabapentin: A placebo-controlled study, Journal of Clinical Psychopharmacology, 19, 341, 10.1097/00004714-199908000-00010 · DOI
  49. Potts, 1995, Pharmacological treatments: literature review, 334
  50. Reich, 1988, A pilot study of treatment of social phobia with alprazolam, American Journal of Psychiatry, 145, 590, 10.1176/ajp.145.5.590 · DOI
  51. Rickels, 2004, A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder, Journal of Clinical Psychopharmacology, 24, 488, 10.1097/01.jcp.0000138764.31106.60 · DOI
  52. Rynn, 2001, Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder, American Journal of Psychiatry, 158, 2008, 10.1176/appi.ajp.158.12.2008 · DOI
  53. Schneier, 1995, Clinical assessment strategies for social phobia, Psychiatric Annals, 25, 550, 10.3928/0048-5713-19950901-09 · DOI
  54. Schneier, 1992, Fluoxetine in social phobia, Journal of Clinical Psychopharmacology, 12, 62, 10.1097/00004714-199202000-00018 · DOI
  55. Schneier, 1993, Buspirone in social phobia, Journal of Clinical Psychopharmacology, 13, 251, 10.1097/00004714-199308000-00004 · DOI
  56. Schneier, 1998, Placebo-controlled trial of moclobemide in social phobia, British Journal of Psychiatry, 172, 70, 10.1192/bjp.172.1.70 · DOI
  57. Schutters, 2005, Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study, Journal of Clinical Psychiatry, 66, 540, 10.4088/JCP.v66n0420b · DOI
  58. Schutters, 2010, Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study, International Clinical Psychopharmacology, 25, 302, 10.1097/YIC.0b013e32833a4d71 · DOI
  59. Seedat, 2004, Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder, Journal of Clinical Psychiatry, 65, 244
  60. Simeon, 1987, Alprazolam effects in children with anxiety disorders, Canadian Journal of Psychiatry, 32, 570, 10.1177/070674378703200712 · DOI
  61. Simeon, 1992, Clinical, cognitive, and neurophysiological effects of alprazolam effects in children and adolescents with overanxious disorder and avoidant disorders, Journal of American Academy of Child and Adolescent Psychiatry, 31, 29, 10.1097/00004583-199201000-00006 · DOI
  62. Simon, 2004, An open-label study of levetiracetam for the treatment of social anxiety disorder, Journal of Clinical Psychiatry, 65, 1219, 10.4088/JCP.v65n0909 · DOI
  63. Simon, 2006, An open-label trial of risperidone augmentation for refractory anxiety disorders, Journal of Clinical Psychiatry, 67, 381, 10.4088/JCP.v67n0307 · DOI
  64. Simon, 2002, Citalopram for social anxiety disorder: An open-label pilot in refractory and nonrefractory patients, CNS Spectrums, 7, 655, 10.1017/S1092852900022148 · DOI
  65. Simpson, 1998, Imipramine in the treatment of social phobia, Journal of Clinical Psychopharmacology, 18, 132, 10.1097/00004714-199804000-00005 · DOI
  66. Simpson, 1998, Low dose selegiline (L-Deprenyl) in social phobia, Depression and Anxiety, 7, 126, 10.1002/(SICI)1520-6394(1998)7:3<126::AID-DA5>3.0.CO;2-9 · DOI
  67. Stein, 1998, Paroxetine treatment of generalized social phobia (social anxiety disorder), JAMA: the journal of the American Medical Association, 280, 708, 10.1001/jama.280.8.708 · DOI
  68. Stein, 1999, Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study, American Journal of Psychiatry, 156, 756, 10.1176/ajp.156.5.756 · DOI
  69. Stein, 2004, Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions, Depression and Anxiety, 20, 175, 10.1002/da.20043 · DOI
  70. Stein, 2002, Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials, Journal of Clinical Psychiatry, 63, 152, 10.4088/JCP.v63n0211 · DOI
  71. Stein, 2002, Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder, International Journal of Clinical Psychopharmacology, 17, 161, 10.1097/00004850-200207000-00002 · DOI
  72. Stein, 2002, Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study, Archives of General Psychiatry, 59, 1111, 10.1001/archpsyc.59.12.1111 · DOI · Paper page
  73. Stein, D.J., Ipser, J.C., & Balkom, A.J. (2004). Pharmacotherapy for social phobia. Cochrane Database Systematic Review, 4, CD001206. · DOI
  74. Stein, 2005, Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial, Psychopharmacology, 177, 280, 10.1007/s00213-004-1957-9 · DOI
  75. Stein, 1999, A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa, SAMJ. South African medical journal, 89, 402
  76. Sternbach, 1990, Fluoxetine treatment of social phobia, Journal of Clinical Psychopharmacology, 10, 230, 10.1097/00004714-199006000-00024 · DOI
  77. Tata, 2006, Topiramate for binge-eating disorder associated with obesity, Annals of Pharmacotherapy, 40, 1993, 10.1345/aph.1H178 · DOI
  78. Turner, 1994, Social phobia: a comparison of behavior therapy and atenolol, Journal of Consulting and Clinical Psychology, 62, 350, 10.1037/0022-006X.62.2.350 · DOI
  79. Van Ameringen, 1993, Fluoxetine efficacy in social phobia, Journal of Clinical Psychiatry, 54, 27
  80. Van Ameringen, 2001, Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study, American Journal of Psychiatry, 158, 275, 10.1176/appi.ajp.158.2.275 · DOI
  81. Van Ameringen, 1996, Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia, Journal of Affective Disorders, 39, 115, 10.1016/0165-0327(96)00030-4 · DOI
  82. Van Ameringen, 2007, Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial, Journal of Clinical Psychiatry, 68, 288, 10.4088/JCP.v68n0215 · DOI
  83. Van Ameringen, 2004, An open trial of Topiramate in the treatment of generalized social phobia, Journal of Clinical Psychiatry, 65, 1674, 10.4088/JCP.v65n1213 · DOI
  84. Van Ameringen, 2004, Predictors of response in generalized social phobia: Effect of age of onset, Journal of Clinical Psychopharmacology, 24, 42, 10.1097/01.jcp.0000104909.75206.6f · DOI
  85. van der Linden, 2000, The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): A meta-analysis of randomized controlled trials, International Journal of Clinical Psychopharmacology, 2, 15, 10.1097/00004850-200008002-00004 · DOI · Paper page
  86. Van Veen, 2002, Mirtazapine in social anxiety disorder: a pilot study, International Journal of Clinical Psychopharmacology, 17, 315, 10.1097/00004850-200211000-00008 · DOI
  87. van Vliet, 1992, Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor, European Journal of Neuropsychopharmacology, 2, 21, 10.1016/0924-977X(92)90032-4 · DOI
  88. van Vliet, 1994, Psychopharmacological treatment of social phobia: a double-blind placebo controlled study with fluvoxamine, Psychopharmacology, 115, 128, 10.1007/BF02244762 · DOI
  89. Van Vliet, 1997, Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study, Journal of Clinical Psychiatry, 58, 164, 10.4088/JCP.v58n0405 · DOI
  90. Vasudev, K., Macritchie, K., Geddes, J., Watson, S., & Young, A. (2006). Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Systematic Review, 1, CD003384. · DOI
  91. Versiani, 1997, Double-blind placebo controlled trials with bromazepam, Jornal Brasileiro de Psiquiatria, 46, 167
  92. Versiani, 1988, Tranylcypromine in social phobia, Journal of Clinical Psychopharmacology, 8, 279, 10.1097/00004714-198808000-00008 · DOI
  93. Versiani, 1989, Fobia social, Jornal Brasileiro de Psiquiatria, 38, 251
  94. Versiani, 1992, Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine, British Journal of Psychiatry, 161, 353, 10.1192/bjp.161.3.353 · DOI
  95. Villarreal, 2000, Treatment of social phobia with the dopamine agonist pergolide, Depression and Anxiety, 11, 45, 10.1002/(SICI)1520-6394(2000)11:1<45::AID-DA8>3.0.CO;2-8 · DOI
  96. Westenberg, 2004, A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder, Journal of Clinical Psychopharmacology, 24, 49, 10.1097/01.jcp.0000104906.75206.8b · DOI
  97. Zhang, 2005, Levetiracetam in social phobia: a placebo controlled pilot study, Psychopharmacology, 19, 551, 10.1177/0269881105056526 · DOI
  98. Zitrin, 1983, Treatment of phobias: I. A comparison of imipramine hydrochloride and placebo, Archives of General Psychiatry, 40, 125, 10.1001/archpsyc.1983.01790020019002 · DOI

Cited by

Sorted by citations

See all 2

Metadata

Authors
Blanco, C., Bragdon, L., Schneier, F. R., & Liebowitz, M. R.
ORCID
Venue
Social Anxiety
Publisher
Elsevier
Published
2014
Pages
625-659
DOI
10.1016/b978-0-12-394427-6.00022-4
OpenAlex
W3023291234
Cited by
2
References
17
Citations by year
2025: 1 · 2023: 1
FWCI
0.00
Type
book chapter
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
Elsevier eBooks (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Keywords
social anxiety disorder, psychopharmacological treatment, selective serotonin reuptake inhibitors, venlafaxine, benzodiazepines, gabapentin, monoamine oxidase inhibitors, treatment-resistant anxiety, augmentation therapy, cognitive behavioral therapy, safety and tolerability, co-occurring disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review